MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
0.7764
-0.0146
-1.85%
Opening 12:08 03/14 EDT
OPEN
0.7510
PREV CLOSE
0.7910
HIGH
0.7910
LOW
0.7300
VOLUME
12.04K
TURNOVER
--
52 WEEK HIGH
2.610
52 WEEK LOW
0.6208
MARKET CAP
25.38M
P/E (TTM)
-4.0207
1D
5D
1M
3M
1Y
5Y
1D
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
Barchart · 3d ago
Weekly Report: what happened at PMN last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at PMN last week (0224-0228)?
Weekly Report · 03/03 11:47
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial
TipRanks · 02/25 12:33
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
TipRanks · 02/25 12:32
PROMIS NEUROSCIENCES INC - PRECISE-AD STUDY TO ENROLL APPROXIMATELY 100 SUBJECTS ACROSS 22 SITES
Reuters · 02/25 12:00
PROMIS NEUROSCIENCES DOSES FIRST PATIENTS IN PHASE 1B PRECISE-AD TRIAL OF PMN310 FOR ALZHEIMER’S DISEASE
Reuters · 02/25 12:00
Weekly Report: what happened at PMN last week (0217-0221)?
Weekly Report · 02/24 11:47
More
About PMN
More
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Recently
Symbol
Price
%Change

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.